Long-term therapy of elagolix + add-back therapy in women with endometriosis-associated pain for 48 months: a safety update on bone mineral density data of a phase 3 study

To report the 48-month bone mineral density data of a phase 3 study evaluating the long-term safety of elagolix 200 mg twice daily (ELA) with add-back therapy (AB, estradiol 1 mg/0.5 mg norethindrone acetate) for treatment of endometriosis-associated pain (EAP; NCT03213457).

Source: Fertility and Sterility - October 1, 2023 Category: Reproduction Medicine Authors: James A. Simon, Jin Hee Kim, James W. Thomas, Juki Ng, Paul B. Miller, Anna Chan, Michael C. Snabes Source Type: research